不良研究所

ioMicroglia鈩� is set to accelerate research and drug discovery for neurodegenerative disease.

不良研究所 launches the first commercially available human iPSC-derived disease models for Parkinson鈥檚 disease that carry the PRKN R2...

不良研究所 launches early access to ioSensory Neurons for chronic pain research and therapeutics development for peripheral neuropath...

Products aim to address the translation gap and accelerate research and drug discovery for neurodegenerative disease.

The new Huntington鈥檚 disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.

This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.